Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

Study Overview
=================
Brief Summary
-----------------
IL-6 is an inflammatory marker, secrete by the cells in many pathological conditions like COVID-19 pneumonia. Interleukin 6 bind with its receptors (IL-6R) on cells surface and recruited a protein for its activation known as gp-130. Activated receptors send signals to nucleus through secondary messenger system and up regulate the expression of IL-6/GP130 domain. Total of two hundred (n=200) participants were included in the current study and divided equally in four groups. Group B is given Tocilizumab and Group C is treated with Remdesivir along with the approved standard treatment. Group D is only Given standard therapy and Group A constituted normal healthy age and sexed matched participants. Levels of gp-130 were estimated by commercially available ELISA kit. To estimate the relationship of severity of disease with gp-130 and IL-6 Pearson's correlations was used. Sensitivity and specificity for what purpose

Official Title
-----------------
Theranostic Implication of Complimentary Medicines Against IL-6/Gp-130 in COVID-19.: An in Vitro and in Silco Approach

Conditions
-----------------
Corona Virus Disease 2019 (COVID-19)

Intervention / Treatment
-----------------
* Drug: Tocilizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Admitted diagnosed cases of COVID-19 infection on real time polymerase chain reaction (RT-PCR) Both male and female were included All participants were on oxygen therapy Exclusion Criteria: Asthmatics pulmonary fibrosis chronic obstructive pulmonary disease (COPD) Allergic to remdesivir Allergic to Actemra Refused to take consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control<br> | |
| Experimental: Tocilizumab<br> | Drug: Tocilizumab<br>* Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls<br>* Other names: No treatment is given to control group;|
| Experimental: Remdesivir<br> | Drug: Tocilizumab<br>* Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls<br>* Other names: No treatment is given to control group;|
| Active Comparator: Standard Treatment<br> | Drug: Tocilizumab<br>* Comparison of drugs, Tocilizumab, Remdesivir, standard treatment with controls<br>* Other names: No treatment is given to control group;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Ratio of partial pressure of oxygen in arterial blood to fraction of inhaled oxygen |  | 7 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hospital stay |  | 15 days | 
| Oxygen demand |  | 7-15 days | 
| Viral load | by RT-PCR | 7-15 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
corona virus disease 2019 (COVID-19), Tocilizumab, Remdesivir, Interleukin receptor-6, glycoprotein-130, receptor blocker